X4 Pharmaceuticals (XFOR)
(Delayed Data from NSDQ)
$0.71 USD
0.00 (-0.13%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $0.70 -0.01 (-0.86%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
X4 Pharmaceuticals, Inc. [XFOR]
Reports for Purchase
Showing records 1 - 20 ( 96 total )
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Earlier-Than-Expected Revenue; Full Phase 2 CND Data Expected in November; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Knee-Jerk Reaction Provides Opportunity; Positive Interim Readout Bodes Well for 4WARD Success; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eyes on Clinical Data Updates on CND Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Mavorixafor Gained FDA Approval, Launch Underway; New $5 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eyes on Mavorixafor April 30 PDUFA in WHIM Syndrome; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Promising Additional Phase 2 Data in CND; Awaiting Next Clinical Update in 1H24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PDUFA Date Set; Initiation of Phase 3 Study in CND in 1H24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
NDA Filing in WHIM Imminent; Positive Phase 2 Update Supports Mavorixafor?s Potential in CND; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
NDA Filing in WHIM Imminent; KOL Event on May 16; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
NDA Filing in WHIM and Long-term Chronic Neutropenia Data in 2H23; PT Lowered To $3; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Successful 4WHIM Paves Way For 1H24 Launch; Raise PT to $5; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on 4WHIM Top-Line in 4Q22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Mavorixafor Scores in Chronic Neutropenia; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Key Readouts Remain on Track; Lower PT to $3.50 on Dilution; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Strategic Operational Restructuring to Extend Cash Runway into 3Q23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: X4 Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department